

REMARKS / ARGUMENTS

In response to the Final Office Action of June 12, 2009, Applicants have amended the specification and claims, which when considered with the following remarks, is deemed to place the present application in condition for allowance. Favorable consideration of all pending claims is respectfully requested.

Claims 1, 3-12 and 14-16 have been cancelled. Claims 2 and 13 have been amended and new dependent claims 17-24 have been added. Claim 2 is placed in independent form and claims 13 and 17-24 have been made dependent upon claim 2. Support for the amendments in claim 2 can be found in claims 1 and 3, now cancelled. Support for new dependent claims 17-19 can be found in Applicants' specification on page 10, third paragraph and page 12, fourth paragraph. Support for new dependent claims 20-24 can be found on Applicants' specification on page 20, second paragraph from page bottom, as the terms "aliphatic" and "araliphatic" have been defined on the basis of the text on pages 3 and 5, respectively, by taking into account the definition of "substituted NH" as defined on page 4 and the definition of "alkanoyl" on page 8. Thus, claims 2, 13 and 17-24 are fully supported by Applicants' specification and no new matter is added.

Applicants gratefully acknowledges the allowability of claims 2, 3 and 13. Claims 1, 4-12 and 14-16 have been cancelled, without prejudice, due to their recitation of alleged non-elected subject matter. Applicants reserve the right to file one or more continuation or divisional applications directed to the subject matter of the canceled claims.


Claims 1, 4, 8, 9, 12, 14 and 16 have been objected to due to their recitation of non-elected subject matter. As indicated above, these claims have been cancelled rendering moot the objection, and withdrawal of the objection is therefore respectfully requested.

Claim 1 has been objected to for containing a duplication of steps (i) and (ii). Cancellation of this claim renders moot this objection and withdrawal of the objection is respectfully requested.

In view of the foregoing remarks and amendments, it is firmly believed that the present application is in condition for allowance, which action is earnestly solicited.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9499

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Joseph Majka", written over a horizontal dotted line.

Joseph Majka
Attorney for Applicant
Reg. No. 30,570

Date: October 29, 2009